A5065685187- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Medical Imaging Techniques and Applications
- Immunotherapy and Immune Responses
- Cutaneous Melanoma Detection and Management
- Tryptophan and brain disorders
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Stress, Anesthesia, and Immune Response
- Brain Metastases and Treatment
- Nonmelanoma Skin Cancer Studies
- Cancer survivorship and care
- PI3K/AKT/mTOR signaling in cancer
- Renal cell carcinoma treatment
- COVID-19 and healthcare impacts
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer-related cognitive impairment studies
- Ocular Oncology and Treatments
- HER2/EGFR in Cancer Research
- Adrenal Hormones and Disorders
- Hepatitis B Virus Studies
- Skin Protection and Aging
- Immune Cell Function and Interaction
University of Antwerp
2022-2024
Antwerp University Hospital
2024
Vlaamse Vereniging voor Obstetrie en Gynaecolo
2021-2023
Cancer Research Institute Ghent
2019-2022
Ghent University Hospital
2013-2022
Ghent University
2014-2022
Universitair Ziekenhuis Brussel
2014-2020
Institute of Pharmacology
2020
Universitätsmedizin Göttingen
2017
University of Manchester
2017
Importance Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and PD-1 ligand have improved the outcome for many cancer types, majority of patients fails to respond ICI monotherapy. Hypofractionated radiotherapy has potential improve therapeutic ratio ICIs. Objective To assess addition ICIs compared with monotherapy in advanced solid tumors. Design, Setting, Participants This open-label, multicenter, randomized phase 2 trial was conducted 5 Belgian...
The incidence of immune-related adverse events is growing as the use checkpoint inhibitors exponentially increasing. Cutaneous are among most frequent events. purpose this case report and literature review to highlight psoriasis a potential event with need for early recognition.We describe 65-year-old woman exacerbation while treated nivolumab (anti-PD-1) stage IV melanoma. She had history scalp but she presented psoriatic lesions on both lower upper limbs. Our patient was topical steroids....
Indoleamine 2,3-dioxygenase (IDO) is an emerging immunomodulating factor in cancer. IDO expression tumour-negative sentinel lymph nodes (SLNs) of patients with melanoma has a negative prognostic value.To analyse the pattern and associated immunological changes corresponding primary melanomas (PMs), SLNs metastases.In 120 melanoma, PMs (n = 85) metastases 18) were analysed by immunohistochemical staining for FoxP3. Tumour-infiltrating lymphocytes (TILs) scored. stimulated peripheral blood...
Purpose: This longitudinal survey study aimed to investigate the self-reported outcome measures of COVID-19 peritraumatic distress, depression, anxiety, stress, quality life (QOL), and their associated factors in a cohort cancer patients treated at tertiary care hospital during SARS-CoV-2 pandemic. Methods: Surveys were administered four time points between 1 April 2020 18 September 2020. The surveys included CPDI, DASS-21, WHOQOL-BREF questionnaires. Results: Survey response rates high...
Abstract We investigated whether CD4 + -T cells with specificity for an antigen in cardiomyocytes promote the progression from hypertrophy to heart failure mice increased pressure load due transverse aortic constriction (TAC). OT-II expressing a transgenic T cell receptor (TCR) ovalbumin (OVA) on and cMy-mOVA OVA were crossed. The resulting cMy-mOVA-OT-II did not display signs of spontaneous autoimmunity despite fact that their OVA-specific anergic. After TAC, was significantly accelerated...
Several epidemiological studies show an alarming global increase in incidence of melanoma and nonmelanoma skin cancer.To examine the cost-effectiveness 2 population-based cancer screening methods to assess their budget effect influence on findings.A Markov model with a latent period 20 years time horizon 50 was used analyze (societal perspective) (public health care payer programs Belgium compared absence program. A economic analysis based clinical trial performed 2014 Belgium. In model,...
Antibodies blocking programmed cell death 1 (PD-1) have encouraging responses in patients with metastatic melanoma. Response to anti-PD-1 treatment requires pre-existing CD8+ T cells that are negatively regulated by PD-1-mediated adaptive immune resistance. Unfortunately, less than half of melanoma tumours these characteristics. Combining other immunomodulating treatments activate is therefore vital importance increase response rates and long-term survival benefit patients. Both preclinical...
Targeting immune checkpoint molecules has become a major new strategy in the treatment of several cancers. Indoleamine 2,3-dioxygenase (IDO)-inhibitors are potential next-generation immunotherapy, currently investigated multiple phase I-III trials. IDO is an intracellular immunosuppressive enzyme and its expression/activity been associated with worse prognosis The aim this study was to investigate expression pattern colorectal cancer (CRC). In cohort 94 CRC patients, primary tumors (PTs)...
Patients with advanced BRAFV600 mutant melanoma who progressed on prior treatment BRAF-/MEK-inhibitors and programmed cell death 1 or cytotoxic T-lymphocyte-associated antigen 4 immune checkpoint inhibitors can benefit from retreatment the combination of a BRAF- MEK-inhibitor (‘rechallenge’). Hydroxychloroquine prevent autophagy-driven resistance improve efficacy in preclinical models. This clinical trial investigated use combined BRAF-/MEK-inhibition dabrafenib trametinib plus...
Purpose: To report the first case of corneal graft rejection presumably associated with pembrolizumab immunotherapy. Methods: Case and literature review. Results: An asymptomatic 85-year-old woman a history bilateral penetrating keratoplasty presented for follow-up visit diffuse keratic precipitates subepithelial infiltrates. There were no anterior chamber cells. Bilateral subclinical was suspected. Three months previously, immunotherapy started metastatic urothelial cell tumor. Corneal...
Abstract Background While the introduction of checkpoint inhibitors (CPIs) as standard care treatment for various tumor types has led to considerable improvements in clinical outcome, majority patients still fail respond. Preclinical data suggest that stereotactic body radiotherapy (SBRT) could work synergistically with CPIs by acting an situ cancer vaccine, thus potentially increasing response rates and prolonging disease control. Though SBRT administered concurrently been shown be safe,...